# A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma

> **NCT00684827** · PHASE2 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI
- **DRUG:** Racemic Albuterol followed by levalbuterol HFA MDI

## Key facts

- **NCT ID:** NCT00684827
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2003-02
- **Final completion:** 2003-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2012-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684827, "A Safety and Tolerability Study of Levalbuterol HFA Metered Dose Inhaler in Subjects With Asthma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00684827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*